AAAdela Anguisaca

Adela Anguisaca

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Adela Anguisaca has a total of 5 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Ecografía portátil de mano como alternativa accesible en países con recursos limitados

    by Cristina Chediak, Adela Anguisaca, Meri Magoli Orna, Belen Larco, Mayra Oñate, Juan Santacruz

    Background: Percutaneous native kidney biopsy (PNKB) is crucial for diagnosing renal pathology. In resource-limited environments, handheld ultrasound devices may offer a cost-effective alternative for procedural guidance. We aimed to compare the safety and diagnostic yield of PNKB performed with handheld versus high-end ultrasound systems. Methods: retrospective cohort study at Calderón General Teaching Hospital (2021–2023), including adult patients undergoing ultrasound-guided PNKB. Procedures were categorized by device: handheld (Butterfly iQ with iPhone) versus high-end (Philips Sparq). We collected data on demographics, biopsy indications, number of passes, glomerular yield, histological diagnosis, and complications. Diagnostic adequacy and safety outcomes were compared using chi-square and t-tests. Results: A total of 57 PNKBs were analyzed (22 handheld; 35 high-end). Patients were 56% female, with a mean age of 33.8 ± 12.7 years. The average number of glomeruli obtained per core was 15.7 ± 8.1. Overall, 82.5% of procedures were free of complications; 17.5% had minor complications (pain ≥12 h, hematoma, or macroscopic hematuria), and no major complications occurred. Complication-free rates were similar between groups (handheld: 72.7% vs. high-end: 88.6%; p = 0.39). Diagnostic adequacy was achieved in 85.7% of biopsies, with no significant difference between handheld (81.8%) and high-end (88.2%; p = 0.50). Conclusion: Handheld ultrasound-guided PNKB demonstrates comparable safety and diagnostic yield to high-end systems, offering a low-cost and effective alternative in resource-limited settings. Wider adoption may enhance access to renal biopsy without compromising quality or safety.